Sign In
Buy MNKD
$4.13
+0.240 (+6.17%)
At Close: Jul 24, 2026
MannKind (MNKD) Reports Break-Even Earnings for Q2
06:54pm, Monday, 07'th Aug 2023
MannKind (MNKD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.11 per share a year ago.
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
04:00pm, Monday, 31'st Jul 2023
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 second quarter financial results and year to date financial res
Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now
07:31am, Thursday, 13'th Jul 2023
The tech and growth segments of the market have been having a tremendous 2023 with one glaring exception. Traders have been choosing to avoid biotech stocks amid macroeconomic uncertainty around the s
MannKind shares fall after fire that may delay clinical trial
08:27am, Monday, 03'rd Jul 2023
Shares of MannKind Corp. MNKD, +2.78% fell 1.5% premarket on Monday after the biopharma company said a fire at a German manufacturing facility may delay the planned initiation later this year of a pha
7 Overvalued Penny Stocks to Sell Before June 2023
07:49pm, Sunday, 28'th May 2023
While there are plenty of bargains to buy among penny stocks, there are also a good amount of overvalued penny stocks to sell. While significantly lower-priced now than they were at their respective h
Why Shares of MannKind Are Up Wednesday
12:02pm, Wednesday, 10'th May 2023
MannKind had a big jump in revenue year over year. The company has benefitted from its collaboration agreement with United Therapeutics.
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
06:00am, Wednesday, 10'th May 2023
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic pro
MannKind Corporation (MNKD) Q1 2023 Earnings Call Transcript
09:29pm, Tuesday, 09'th May 2023
MannKind Corporation (NASDAQ:MNKD ) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Michael Castagna - CEO Steven Binder - CFO Conference Call Participants Oren Livnat - H
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
06:20pm, Tuesday, 09'th May 2023
MannKind (MNKD) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.10 per share a year ago.
MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
05:00pm, Tuesday, 02'nd May 2023
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 first quarter financial results and its management will host a c
MannKind Corporation (MNKD) Q4 2022 Earnings Call Transcript
09:38am, Friday, 24'th Feb 2023
MannKind Corporation (NASDAQ:MNKD ) Q4 2022 Results Conference Call February 23, 2023 5:00 PM ET Company Participants Michael Castagna - Chief Executive Officer Steven Binder - Chief Financial Officer
MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
05:00pm, Thursday, 16'th Feb 2023
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 fourth quarter and full year financial results and its manageme
MannKind Corporation: MNKD 101 Milestone Shows Promise
07:23pm, Monday, 13'th Feb 2023
MannKind is positioned for growth with the clofazimine inhalation suspension advancing to a Phase 2/3 study and recognition of NTM infection as a global health concern. MannKind's innovative direct de
3 Biotech Stocks Under $15 Worth a Second Look in 2023
08:00am, Wednesday, 18'th Jan 2023
All three stocks have promising therapies that could drive revenue in the coming years.
6 Favorite Biotech Bets For 2023
10:48am, Monday, 09'th Jan 2023
Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's
